https://medtechnews.uk/diabetes-management/yale-researchers-teplizumab-triumph-delaying-the-onset-of-type-1-diabetes/
Yale Researcher’s Teplizumab Triumph: Delaying the Onset of Type 1 Diabetes – MedTechNews
Jan 17, 2025 - Summary Teplizumab, a novel immunotherapy drug, has shown promising results in delaying the onset of type 1 diabetes in clinical trials led by Yale...
the onsetyaleteplizumabtriumphdelaying
https://www.sanofi.com/en/clinical-trials/nct07457580
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access...
This study is a multi-country, multi-center retrospective observational cohort study based on secondary data collected via chart review, with the aim of...
real worldmanaged accessstudypatientstype
https://www.prixgalien.it/teplizumab-sanofi/
Teplizumab: prima terapia modificante del T1D | Prix Galien Italia
Sep 14, 2026 - Teplizumab è la prima terapia modificante il decorso del diabete di tipo 1. Un anticorpo anti-CD3 che può ritardare la progressione dal T1D di stadio 2.
teplizumabprimaterapiamodificantedel
https://www.diabete.com/diabete-1-bari-primi-trattamenti-pediatrici-teplizumab/
Diabete tipo 1: a Bari tra i primi trattamenti pediatrici con teplizumab per ritardare l’esordio...
Mar 3, 2026 - Diabete tipo 1: un ragazzo in fase preclinica trattato con teplizumab, per rallentare progressione della malattia prima della comparsa dei sintomi.
diabetetipobaritraprimi